Viridian Therapeutics (VRDN) – Analysts’ Recent Ratings Updates

Viridian Therapeutics (NASDAQ: VRDN) recently received a number of ratings updates from brokerages and research firms:

• 11/7/2026 – Viridian Therapeutics was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 11/5/2026 – Viridian Therapeutics had its price target raised by Royal Bank Of Canada from $38.00 to $41.00. They now have an “outperform” rating on the stock.
• 11/5/2026 – Viridian Therapeutics had its price target raised by Leerink Partners from $50.00 to $54.00. They now have an “outperform” rating on the stock.
• 11/5/2026 – Viridian Therapeutics had its price target raised by Truist Financial from $39.00 to $42.00. They now have a “buy” rating on the stock.
• 11/5/2026 – Viridian Therapeutics had its price target raised by Wells Fargo & Company from $31.00 to $34.00. They now have an “overweight” rating on the stock.
• 11/5/2026 – Viridian Therapeutics had its price target raised by Wedbush from $41.00 to $42.00. They now have an “outperform” rating on the stock.
• 11/5/2026 – Viridian Therapeutics had its price target raised by HC Wainwright from $22.00 to $40.00. They now have a “buy” rating on the stock.
• 11/4/2026 – Viridian Therapeutics had its price target raised by Needham & Company LLC from $34.00 to $38.00. They now have a “buy” rating on the stock.
• 10/4/2026 – Viridian Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/26/2026 – Viridian Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/22/2026 – Viridian Therapeutics had its price target raised by Royal Bank Of Canada from $36.00 to $38.00. They now have an “outperform” rating on the stock.
• 9/14/2026 – Viridian Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Viridian Therapeutics Price Performance

Shares of Viridian Therapeutics stock opened at $30.48 on Friday. The firm has a market capitalization of $3.46 billion, a PE ratio of -7.94 and a beta of 1.07. The company has a current ratio of 14.46, a quick ratio of 14.46 and a debt-to-equity ratio of 0.50. Viridian Therapeutics, Inc. has a 12 month low of $13.18 and a 12 month high of $34.29. The business’s 50-day moving average price is $22.59 and its 200-day moving average price is $21.77.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.21. The company had revenue of $25.75 million during the quarter, compared to the consensus estimate of $4.72 million. Viridian Therapeutics had a negative return on equity of 79.67% and a negative net margin of 1,620.79%. Sell-side analysts forecast that Viridian Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of Viridian Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.40% of the company’s stock.

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.